Silk Road Medical, which sells medical devices used in TCAR for the treatment of carotid artery disease, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Sunnyvale, CA-based company was founded in 2007 and booked $35 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol SILK. Silk Road Medical filed confidentially on December 19, 2018. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
The article TCAR device maker Silk Road Medical files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Read More: https://www.nasdaq.com/article/tcar-device-maker-silk-road-medical-files-for-a-86-million-ipo-cm1108850
Tepha Inc. Announces Initiation of Clinical Evaluation of P4HB™ Regenerative Scaffold for Stress Urinary Incontinence
Via: PR Newswire
LEXINGTON, Mass., Feb. 27, 2019 /PRNewswire/ -- Tepha Inc. announced today the initiation of a pilot clinical evaluation of the Company's P4HB regenerative polymer scaffold for the surgical treatment of stress urinary incontinence (SUI). The study was initiated in Cape Town, South Africa in partnership with the Pelvic Floor Foundation of South Africa ("PFFSA") and the University of Cape Town. The first procedures were performed by co-principal investigators, Dr. Stephen Jefferyof the University of Cape Town and Professor Jan-Paul Roovers of the Academic Medical Center, Amsterdam, The Netherlands. The Cape Town SUI study represents the first clinical application of Tepha's P4HB polymer technology in the field of urogynecology. Based in Lexington, MA, Tepha is the pioneer developer and exclusive supplier of the P4HB polymer for medical applications that include hernia repair, plastic surgery, tendon & ligament repair, and wound closure.
After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger and two others.
1NEWSISET 2019Surmounting Minor Stroke: New Devices, TCAR Aim to Cut Risk of Carotid Artery Stenting
Embolic protection, new stents, and TCAR are narrowing the gap between CAS and CEA, but medical therapy could still hold its own in CREST-2.
Dr. Michael Aragon and Stacey Porter Bring Wealth of Clinical and Organizational Expertise During Time of Company Grow
A Silicon Valley startup that pioneered a new way to fight diabetes is tackling depression after its CEO noticed a disturbing trend
Via: Business Insider
When Sean Duffy, the cofounder and CEO of a digital-health startup called Omada Health, took his first look at the results of his new diabetes-treatment program, he noticed a disturbing trend.
Blue Cross Blue Shield of Massachusetts Adds Two New Digital Health Solutions for Large Self-insured Clients
Via: PR Newswire
BOSTON, Jan. 8, 2019 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts (Blue Cross) recently added two new digital health solutions to its Emerging Solutions portfolio—Robin Care for cancer support and Hinge Health for musculoskeletal conditions such as back and knee pain.
Transcarotid artery revascularization with a neuroprotection system was associated with a low rate of stroke in patients with carotid artery stenosis, according to 1-year results of the ROADSTER trial.
Phase 1a Dose-Escalation Data Demonstrates a Favorable Safety Profile and Signals of Immune Cell Modulation in Patients with Late Stage Solid Tumors
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab